Transurban – boring but reliable
Transurban (TCL) is one of my preferred stocks. At what price point would I be a buyer, and at what price would I be a seller?
Browse current and previous editions of Switzer Report
Transurban (TCL) is one of my preferred stocks. At what price point would I be a buyer, and at what price would I be a seller?
In our HOT stock column today, Raymond Chan, Head of Asian Desk, explains why Morgans maintains its HOLD rating for REA, with a BUY rating below $197.
A wind of change has blown through the aged care sector. With a report just released from the Aged Care Taskforce and proposed legislation in the wings, there is at least the feeling that a blueprint for the future of our highly competitive but highly fragmented aged care sector is taking shape, promising greater regulatory clarity for investors. Here are two well-positioned stocks that could benefit from any changes.
In the early stages of the August reporting season, during the week ending Friday 9 August 2024, FNArena recorded six ratings upgrades and two downgrades for ASX-listed companies by brokers monitored daily.
After the big stocks set off last week, what shares are in the buy zone?
The greatest lesson and insight from this week’s brutal market sell off (and then the rebound that produced the best day since November 2022 for the S&P 500) was the prevailing market belief that there’s another leg up for stocks.
In a week when market negativity might be rattling investors, Tony Featherstone wisely advises to focus on company fundamentals and valuations, not market sentiment.
In our “HOT” stock column, Michael Gable, managing director of Fairmont Equities, explains why shares in Newmont (NEM) are a good buy right now, and should continue to head higher over time.
Why can’t retail investors buy hybrid securities (bank capital notes)? Has CSL finally broken through $300? Why aren’t distributions from Transurban franked? What is the broker target price for Pro Medicus?
Peter Switzer & Paul Rickard answer your questions on ZIP, AD8, STO& more
How scared should you bet about the sell off + stocks with an upside
Just when the data drops in the US were telling us that inflation was falling, rates were about to be cut and the Fed had engineered a soft landing, along came a weaker-than-expected jobs report that has led to recession fears. So, should you be afraid?
In this article, we look at how our income and growth portfolios have performed so far this year.
For our “HOT” stock today, Raymond Chan, Head of Asian Desk at Morgans explains why Morgans considers Resmed (RMD) to be an ADD to an investment portfolio.
Here are two situations where the odds might be on the side of the speculators! But always remember the risk.
You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.